Last reviewed · How we verify
GNT0003
At a glance
| Generic name | GNT0003 |
|---|---|
| Sponsor | Genethon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome (PHASE2)
- Gene Therapy for Severe Crigler Najjar Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GNT0003 CI brief — competitive landscape report
- GNT0003 updates RSS · CI watch RSS
- Genethon portfolio CI